Aimee McGreal-Bellone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aimee McGreal-Bellone has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alina Botgros
Directorate of Infection, Guy’s & St Thomas’ National Health Service Foundation Trust , London , UK
1 shared publicationArthur Jackson
Department of Infectious Disease, Cork University Hospital, Cork, Ireland
1 shared publication- Brendan O'KElly
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
1 shared publication - Catherine Moore
Public Health Wales, Heath Park, Cardiff, UK
1 shared publication - Clemency Nye
Public Health Wales, University Hospital of Wales, Heath Park, Cardiff, CF14 XW
1 shared publication - E J Aarons
Directorate of Infection, Guy’s & St Thomas’ National Health Service Foundation Trust , London , UK
1 shared publication
Latest Publications
- Open Access
- 7 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad612
A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir
The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median, 10 days [range, 10–18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had hematological malignancy and 10 (10/11) had received CD20-depleting therapy. The median duration of infection was 103 days (interquartile range, 85–138 days). The majority (10/11) were hospitalized, and 7 (7/11) had severe/critical disease. All survived and 9 of 11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests that prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.
- 7 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad612
Open AccessA Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir
The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median, 10 days [range, 10–18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had hematological malignancy and 10 (10/11) had received CD20-depleting therapy. The median duration of infection was 103 days (interquartile range, 85–138 days). The majority (10/11) were hospitalized, and 7 (7/11) had severe/critical disease. All survived and 9 of 11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests that prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.
- 12 November 2021
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 191 (5) , 2221-2222
Letter to the editor regarding penicillin allergy de-labelling in Ireland
- 12 November 2021
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 191 (5) , 2221-2222
Letter to the editor regarding penicillin allergy de-labelling in Ireland